The Future of Biomarker Research: Accelerating Innovations

Biomarkers have evolved from simple disease indicators to essential tools in clinical trials, enabling researchers to monitor disease progression and evaluate treatment effectiveness. 

Michael Miller, Chief Operating Officer, shared with Pathology In Practice, that recently validated blood-based biomarkers, such as p-tau217, enable earlier and more confident Alzheimer’s diagnosis without costly PET or CSF tests—reducing delays, lowering healthcare burden, expanding global access and allowing patients to start potentially more effective treatments sooner. 

Read the article to learn how collaboration between diagnostic and pharmaceutical leaders can accelerate biomarker discovery and development, providing researchers with resources and a streamlined path from early research to clinical applications, ensuring treatments reach the patients that need them most.